Skip to main content
    F

    FibroGen Inc (FGEN)

    Official site

    BIOTECHNOLOGY

    $9.71
    +0.69 (+7.65%)

    Last updated: Jan 07, 2026 at 4:00 PM ET

    FibroGen Inc (FGEN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2025. Financial statements from company filings, amounts in US dollars.

    FibroGen reported revenue of $29.62M for the fiscal year ended Dec 31, 2024, down 36.7% from the year before. That year, net income was -$47.58M with a net margin of -160.6%, operating cash flow was -$138.00M and free cash flow was -$138.26M. The quarter ended Sep 30, 2025 had revenue of $1.08M and net income of $200.64M.

    Revenue and Margins

    Over the 9 years to Dec 2024, revenue fell from $180.83M, a compound annual decline of 18.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$29.62M-36.7%47.5%-507.8%-160.6%
    Dec 2023$46.80M-66.7%91.5%-689.5%-607.3%
    Dec 2022$140.73M-40.2%85.6%-213.9%-208.7%
    Dec 2021$235.31M+33.5%94.5%-122.6%-123.7%
    Dec 2020$176.32M-31.3%95.0%-108.8%-107.4%
    Dec 2019$256.58M+20.5%99.6%-34.8%-30.0%
    Dec 2018$212.96M+69.5%-10.7%-40.7%-40.6%
    Dec 2017$125.67M-30.0%-56.4%-97.6%-100.4%
    Dec 2016$179.58M-0.7%-4.2%-29.9%-34.3%
    Dec 2015$180.83MN/A-18.4%-42.9%-47.4%
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$29.62M$46.80M$140.73M$235.31M$176.32M$256.58M$212.96M$125.67M$179.58M$180.83M
    Cost of revenue$15.56M$3.96M$20.28M$12.87M$8.87M$1.15M$235.84M$196.52M$187.21M$214.09M
    Gross profit$14.06M$42.84M$120.45M$222.44M$167.45M$255.43M-$22.88M-$70.85M-$7.63M-$33.26M
    Research and development$95.69M$266.47M$296.79M$387.04M$252.92M$209.26M$235.84M$196.52M$187.21M$214.09M
    Operating income-$150.42M-$322.72M-$301.02M-$288.53M-$191.88M-$89.31M-$86.69M-$122.61M-$53.65M-$77.63M
    Net income-$47.58M-$284.23M-$293.65M-$291.03M-$189.29M-$76.97M-$86.42M-$126.20M-$61.68M-$85.78M
    EBITDA-$142.43M-$305.20M-$282.82M-$273.72M-$164.28M-$52.31M-$68.56M-$104.75M-$44.99M-$68.83M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$1.08M$1.35M$2.74M-$123.26M$46.33M$998.00K$25.36M$27.14M$40.13M$44.32M$36.16M$34.37M
    Gross profit$1.13M$1.26M$2.49M-$102.59M$41.04M-$31.50M-$32.47M$21.73M$35.89M$38.61M$32.67M$29.44M
    Operating income-$5.41M-$12.05M-$14.92M-$91.66M-$16.78M-$46.41M-$49.18M-$54.20M-$63.48M-$88.05M-$76.09M-$66.15M
    Net income$200.64M-$7.60M$4.64M$17.98M-$17.08M-$15.54M-$32.93M-$56.23M-$63.62M-$87.68M-$76.70M-$66.17M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, long-term debt of $73.09M exceeded cash and equivalents by $22.61M. Shareholder equity was negative, at -$225.60M, as total liabilities of $398.16M exceeded total assets of $214.53M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$214.53M$423.53M$610.09M$773.82M$826.84M$857.40M$880.60M$898.65M$469.55M$470.57M
    Current assets$196.51M$331.56M$492.83M$474.06M$755.11M$702.49M$690.01M$748.97M$266.52M$200.56M
    Cash and equivalents$50.48M$113.69M$155.70M$171.22M$678.39M$126.27M$89.26M$673.66M$173.78M$153.32M
    Total liabilities$398.16M$585.73M$611.57M$544.71M$385.39M$321.99M$352.13M$316.20M$294.44M$273.75M
    Short-term debtN/A$14.12M$10.29M$10.94M$13.52M$12.35M$1.09M$57.32M$45.03M$43.17M
    Long-term debt$73.09M$71.93MN/AN/AN/A$16.78M$16.80M$17.24M$97.35M$15.09M
    Shareholder equity-$225.60M-$204.17M-$21.45M$209.15M$422.18M$516.13M$509.20M$563.18M$155.84M$177.55M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$137.01M$178.06M$165.21M$214.53M$264.42M$293.20M$365.87M$423.53M$460.43M$515.13M$538.54M$610.09M
    Total liabilities$119.53M$359.08M$340.14M$398.16M$466.12M$483.58M$552.02M$585.73M$575.63M$575.43M$567.43M$611.57M
    Cash and equivalents$117.97M$23.37M$33.61M$50.48M$131.00M$140.71M$105.73M$113.69M$60.81M$152.59M$188.55M$155.70M
    Shareholder equity-$17.03M-$223.00M-$216.90M-$225.60M-$243.67M-$232.34M-$228.12M-$204.17M-$157.17M-$102.27M-$48.85M-$21.45M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$138.00M-$315.02M-$145.93M-$82.23M$81.60M-$78.70M-$76.14M-$66.51M$7.11M-$18.57M
    Capital expenditures$266.00K$2.52M$38.74M$30.19M$3.99M$5.76M$8.02M$8.50M$1.25M$1.98M
    Free cash flow-$138.26M-$317.54M-$184.67M-$112.42M$77.61M-$84.47M-$84.16M-$75.01M$5.86M-$20.55M
    Dividends paid$2.23M$2.25M$5.17M$7.37M$11.46M$12.75MN/A$0$0$0
    Investing cash flow$125.99M$153.66M$89.12M-$426.97M$452.49M$120.02M-$522.12M$69.87M$6.62M-$5.87M
    Financing cash flow-$255.00K$122.75M$46.78M-$563.00K$13.34M-$4.30M$13.88M$496.47M$6.74M$12.35M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$1.85M$12.68M$2.72M-$30.47M-$8.38M-$39.87M-$59.29M-$18.32M-$84.54M-$110.57M-$101.59M-$52.51M
    Capital expenditures$9.00K$13.00K$16.00K$141.00K$82.00K$14.00K$29.00K$251.00K$684.00K$993.00K$591.00K$333.00K
    Free cash flow-$1.86M$12.67M$2.70M-$30.61M-$8.46M-$39.88M-$59.32M-$18.57M-$85.22M-$111.56M-$102.18M-$52.85M
    Last 12 quarters

    Frequently Asked Questions About FGEN

    What is FibroGen's annual revenue?

    FibroGen reported revenue of $29.62M for the fiscal year ended Dec 31, 2024.

    How fast is FibroGen's revenue growing?

    Revenue was down 36.7% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was -49.9%.

    Is FibroGen profitable?

    No. FibroGen reported net income of -$47.58M for the fiscal year ended Dec 31, 2024, with a net margin of -160.6%.

    How much free cash flow does FGEN generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$138.00M minus capital expenditures of $266.00K produced free cash flow of -$138.26M.

    How much debt does FibroGen have?

    The balance sheet dated Dec 31, 2024 reported long-term debt of $73.09M and cash and equivalents of $50.48M.